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Abstract
Background: Using routinely collected patient data we explore the utility of multilevel latent class (MLLC) models
to adjust for patient casemix and rank Trust performance. We contrast this with ranks derived from Trust
standardised mortality ratios (SMRs).
Methods: Patients with colorectal cancer diagnosed between 1998 and 2004 and resident in Northern and
Yorkshire regions were identified from the cancer registry database (n = 24,640). Patient age, sex, stage-at-diagnosis
(Dukes), and Trust of diagnosis/treatment were extracted. Socioeconomic background was derived using the
Townsend Index. Outcome was survival at 3 years after diagnosis. MLLC-modelled and SMR-generated Trust ranks
were compared.
Results: Patients were assigned to two classes of similar size: one with reasonable prognosis (63.0% died within
3 years), and one with better prognosis (39.3% died within 3 years). In patient class one, all patients diagnosed at
stage B or C died within 3 years; in patient class two, all patients diagnosed at stage A, B or C survived. Trusts were
assigned two classes with 51.3% and 53.2% of patients respectively dying within 3 years. Differences in the ranked
Trust performance between the MLLC model and SMRs were all within estimated 95% CIs.
Conclusions: A novel approach to casemix adjustment is illustrated, ranking Trust performance whilst facilitating
the evaluation of factors associated with the patient journey (e.g. treatments) and factors associated with the
processes of healthcare delivery (e.g. delays). Further research can demonstrate the value of modelling patient
pathways and evaluating healthcare processes across provider institutions.
Background
Survival from cancer varies according to many factors
including place of diagnosis and treatment centre
(Trust), [1,2] stage at diagnosis, [3,4] and associated risk
factors such as age at diagnosis, sex, and socioeconomic
background (SEB) [5-9]. Some Trusts perform better or
worse than others in terms of average survival rates per-
haps due to patient casemix at the time of entry into
the healthcare system, though patient outcome differ-
ences will reflect underlying differences in the effective-
ness of healthcare organisations. Much interest lies in
identifying good and poor performing healthcare provi-
ders, to identify best practice and advocate changes in
under-performing institutions. It is important to account
for patient casemix when evaluating institutional perfor-
mance and there are currently several strategies.
Regression (linear or logistic) is a traditional and well-
documented approach, [10] where variables relating to
patient characteristics are modelled, effectively to adjust
the outcome in relation to the likely influences of these
factors. Methods such as matching, stratification, [10] or
propensity score analysis, [11,12] may also be used, though
these techniques make potentially untestable assumptions
and never account for the impact of unmeasured variables
or accommodate Trust-level variation. Although multilevel
modelling accounts for patients nested within Trusts, and
provides improved estimatesc o m p a r e dw i t hl o g i s t i c
regression, [13,14] parametric assumptions are made that
may not be tenable. Other methods, such as boosted deci-
sion trees, [15] have occasionally been used, though these
can be difficult to interpret.
No casemix-adjustment strategy will eliminate all bias
due to unmeasured differences amongst patients; [16]
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patient variation through measured variables only is
crude: models ought to reflect the uncertainty associated
with patient casemix characteristics. Furthermore, case-
mix adjustment does not account for differences in
patient treatments. Failure to capture variation in
patient pathways and their consequences may result
in over-simplistic interpretation of healthcare processes
and consequent outcomes. Models need to accommo-
date patient casemix, the patient experience, and uncer-
tainty in both.
Multilevel latent class (MLLC) modelling is proposed
to: (i) adjust for patient casemix whilst accommodating
uncertainty surrounding unrecorded patient characteris-
tics; (ii) adjust for patient pathways in terms of the
delivery of appropriate healthcare (e.g. treatments); and
(iii) differentiate patient outcomes in relation to institu-
tional process characteristics (e.g. delays to treatment).
To demonstrate and validate all three steps simulta-
neously is challenging. The first of these is explored
here. We contrast the MLLC model ranking of Trust
performance with that of ranks derived from calculating
Trust standardised mortality ratios (SMRs). To illustrate
o u rm e t h o d o l o g y ,w es t u d yr o u t i n ed a t ao nc o l o r e c t a l
cancer patients from a large UK health region.
Methods
The illustrative colorectal cancer dataset
Patients with colorectal cancer (ICD10 [18] codes C18,
C19 and C20) diagnosed between 1998 and 2004 and
resident in the Northern and Yorkshire regions were
identified from the Northern and Yorkshire Cancer Reg-
istry and Information Service (NYCRIS) database.
Patient age, sex, tumour stage at diagnosis (using the
Dukes classification [19]), Trust of diagnosis/treatment,
and whether or not the patient received treatment were
extracted. Initial data extraction yielded 26,455 unique
patient records. Socioeconomic background (SEB) was
defined at the 2001 enumeration district level of resi-
dence (super output area) using the Townsend Index
[20] and matched to patients using postcode. The pri-
mary outcome was dead or alive three years following
diagnosis, which is clinically meaningful since colorectal
cancer has a median survival of approximately three
years and survival to three years is often considered for
policy reasons.
An area deprivation score could not be obtained for
one case. Patients with age at diagnosis greater than
100 years (7 patients) and patients identified by death
certificate only (364; 1.4%) were excluded. Some patients
had multiple diagnosis codes and for patients attending
more than one hospital (16,549; 63%), the location of
t h em o s tr e c e n tT r u s tw i t harelevant diagnosis code
was recorded as the diagnostic/treatment centre, as this
provided the latest staging information. For patients
who did not have a relevant diagnosis code for any
Trust visits (220; 0.83%), the location of their first Trust
visit was taken as the diagnostic/treatment centre. Some
1,239 (4.7%) patients were excluded as their diagnostic
centres were outside the NYCRIS region. Following
exclusions, 24,640 (93%) of the identified patients
remained for analysis.
Statistical methods
Latent class analysis (LCA) is well established within
single-level regression analysis. Also known as discrete
latent variable modelling,o rmixture modelling,o n e
determines a number of latent classes, or subgroups, the
optimum choice of which is typically informed by log-
likelihood statistics. The Bayesian Information Criterion
(BIC), [21] the Akaike Information Criterion (AIC), [22]
and changes in log-likelihood (LL) are used as model-fit
indicators, though models might also be selected on the
basis of interpretation [23]. Model parameters of each
latent class are determined empirically, along with their
contribution to the outcome distribution. LCA models
are useful where subtypes are sought and one wishes to
model uncertainty surrounding class membership, since
observations may belong to all classes, with probabilities
determined empirically. LCA thus reflects the uncer-
tainty associated with a limited number of predictors
when determining subtypes of outcomes. The proposed
LCA models are multilevel because patients are nested
within diagnostic/treatment centres (Trusts). LCA
extends to a multilevel setting by incorporating discrete
latent variables at all levels of the hierarchy. For the col-
orectal cancer data, latent classes at the patient level
model uncertainty surrounding affiliation to patient sub-
groups and latent classes at the Trust level model Trust
variation. The modelling strategy was to determine
patient-level latent classes (having included patient-level
covariates) with Trust-level variation accommodated
initially by a continuous latent variable. With patient-
level subtype structure fixed, Trust classes were then
sought by switching the Trust-level latent variable from
continuous to categorical. A minimum of two Trust
classes was required to exhibit discretised Trust class
differences in patient outcomes.
The proposed modelling strategy builds upon work
originated by Downing et al., [24] where multilevel LCA
circumnavigated potential bias due to the ‘reversal para-
dox’ when adjusting for confounders on the causal path
between exposure and outcome [25]. We have no such
concerns here, since we are not seeking inference of any
exposure nor confounder adjustment: rather, we seek to
optimise outcome prediction by modelling patient char-
acteristics to accommodate casemix differences. Conse-
quently, all available covariates for which there was
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the modelling process, along with stage at diagnosis
(coded A to D for increasing severity and missing coded
X). Stage was included despite a degree of missing data
(13.1%), because it is known to influence survival, [3,4]
and a missing category was conveniently added.
Although additional patient variables were available,
such as time-to-first-treatment and treatment-received,
these had substantial incomplete data that would ques-
tion their utility and were therefore not used. Patient
age at diagnosis and Townsend score (SEB) were contin-
uous measures; age was centred on the study mean (71.5
years) and SEB was centred on the population mean of
zero (study mean was -0.040). Both covariates exhibited
a non-linear relationship with 3-year survival, so a quad-
ratic term for age was included in the model; and by
‘trimming’ the tails of SEB (assigning rare values > ± 5.0
as ± 5.0), it was possible to avoid higher order terms
for Townsend score. The model is described in the
Appendix.
SMRs were calculated for each Trust (standardised by
age, sex, deprivation and stage) and a scaled difference
from ‘SMR = 1’ was determined for each Trust by dividing
by the square root of the Trust size. For both the SMRs
and the MLLC models, 200 bootstrapped datasets were
generated and each was analysed in the same manner to
determine 95% confidence intervals (CIs). We used MLLC
to calculate absolute differences in Trust effects on the log
odds scale (with patient-level values aggregated to the
Trust level) before ranking in order of ‘best’ to ‘worst’ sur-
vival, to compare with the ranks generated from the Trust
SMRs. For data manipulation, summary statistics, tabula-
tion, and charts, Stata was used; [26] for latent variable
models, LatentGold [27] was used.
Results
Table 1 summarises the ‘ideal’ MLLC model determined
by the procedures described. Patients were assigned to
two latent classes of similar size, one with reasonable
prognosis (PC1: 54.3% of cases, of which 63.0% died
within three years), and one with better prognosis (PC2:
45.7% of cases, of which 39.3% died within three years).
Trusts were similarly assigned to two latent classes. The
largest Trust class, with 53.1% of patients, had better
prognosis (TC1: 51.3% of patients died within three
years; TC2: 53.2% of patients died within three years).
Table 2 summarises the number of deaths within each
patient class by stage. Allocating patients to classes
according to their largest class probability (modal
assignment), all patients inP C 1d i a g n o s e de i t h e ra t
stage B or C died within three years; in PC2, all patients
diagnosed at stage A, B or C survived. This difference is
anticipated, as stage at diagnosis is an important predic-
tor of survival. Most of the early- or mid-stage patients
died within three years in PC1 compared to PC2, and
there was a clear graduation in survival with increasing
stage at diagnosis from early- to late-stage within both
classes. The predictor age differed substantially across
classes. In contrast, the predictors deprivation and sex
differed only marginally between patient classes.
Trust ranks and their bootstrapped 95% CIs are sum-
marised in Table 3; a low ranking value indicates a bet-
ter survival rate than expected. Differences in the
median rank of Trust performance between the MLLC
model approach and the Trust SMRs are within their
estimated 95% CIs. Figure 1 provides a graphical repre-
sentation of these results, in order of increasing median
probability of belonging to the best survival Trust class
by the MLLC methodology.
Discussion
In a standard multilevel setting, where a continuous
latent variable is adopted at the Trust level, the
Table 1 Results for the subject classes in the 2-patient,
2-Trust-class multilevel latent class regression model
Model Summary Statistics Class 1 Class 2
Class Size 54.3% 45.7%
Overall Prevalence 63.0% 39.3%
Reference Group Prevalence 23.2% 7.0%
Model Covariates Odds Ratio (95% CI)
Stage = B 2.40 (1.63-3.54) 0.55 (0.21-1.43)
Stage = C 7.72 (4.61-12.94) 1.74 (0.75-4.06)
Stage = D 20.19 (8.88-45.89) Infinite
†
Stage = X 6.30 (1.89-20.97) 33.41 (7.93-140.68)
Female 0.94 (0.78-1.14) 0.58 (0.38-0.88)
Townsend (per SD more) 1.32 (1.21-1.43) 1.03 (0.81-1.31)
Age (per 5 years older) 1.51 (1.42-1.60) 2.53 (1.31-4.90)
Age squared (per 5 years older) 1.005 (0.997-1.012) 0.984 (0.960-1.008)
Odds ratio of death within 3 years. CI: Confidence Interval. There were 12,856
(52.2%) deaths in the study population. The reference group comprised males,
aged 71.5 years, classified as Stage A at diagnosis, and attributed a Townsend
score of zero.
†The odds ratio could not be estimated as there were zero
patients who survived 3 years in this subcategory.
Table 2 Deaths by stage, and patient class, for the 2-
patient, 2-Trust multilevel latent class regression model
Modal Class
12
Stage at Diagnosis Died within 3 years Died within 3 years
No Yes No Yes
A 1099 550 1210 0
B 0 1955 4829 0
C 0 2736 3437 0
D 437 3202 0 1962
X 413 2360 359 91
TOTAL 1949 10803 9835 2053
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an underlying normal distribution (conditional on
Trust-level covariates): Trusts are effectively treated as
a random sample of a larger (infinite) population of
Trusts. Trusts are not, however, randomly placed geo-
graphically and nor are patients randomly assigned to
Trusts. Parametric assumptions were therefore
replaced by other assumptions which are less restric-
tive by adopting discrete latent variables, although
there remains a degree of geographical dependency
that is not accounted for. This remains a limitation.
The simplest MLLC model adopted was therefore
where the continuous latent variable at the upper level
is replaced by a categorical latent variable. The model
estimates the mean outcome for each Trust class and
the size of each Trust class (summation of Trust prob-
abilities for each Trust class) and no assumptions were
made regarding the underlying distribution or class
sizes. More complex models can extend this approach
to accommodate the spatial dependencies, though this
will be part of future developments.
An upper-level discrete latent variable allows for indi-
vidual Trusts to be assigned probabilistically across the
discrete latent classes, providing less restricted weighting
of Trust relative performance. This may improve the
accuracy of the estimated patient outcome differences
Table 3 Trust ranks from the MMLC model and the
calculation of Trust SMRs
Trust Median
probability of
belonging to
best survival
Trust class
Median Rank (95% CI)
ML LC SMR
1 1.000 1 (1-9.5) 6 (2-11)
2 0.999 3 (1-11) 4 (1-10.5)
3 0.997 4 (1-11) 3 (1-10.5)
4 0.996 4 (1-15) 8 (3-14.5)
5 0.993 5 (1-12.5) 5 (1-13)
6 0.956 8 (2-16) 9 (2-17)
7 0.912 9 (3-17) 5 (1-17)
8 0.908 9 (2-17) 6 (1-18)
9 0.897 9 (3-18) 5 (1-18)
10 0.816 10 (3-17) 8 (1-18)
11 0.575 11 (3.5-18) 11 (3-17)
12 0.476 13 (5.5-18) 12.5 (3-18)
13 0.372 12 (4-18.5) 11.5 (5.5-17)
14 0.359 12 (3-19) 12 (7-17)
15 0.152 14 (5.5-19) 15 (4.5-18)
16 0.070 14 (4-19) 13 (7-18)
17 0.070 15 (7.5-19) 16 (7.5-18)
18 0.003 18 (7-19) 15 (10-18)
19 0.002 18 (13.5-19) 19 (18-19)
Figure 1 Trust Median Ranks and 95% Confidence Intervals, ordered by the MMLC analysis.
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patient casemix adjustment for individual Trusts. The
MLLC model is more likely to capture contextual effects
due to the inherent data hierarchy than either a stan-
dard multilevel approach or by merely estimating Trust
ranks according to their SMRs. Continuous and discrete
latent variables, if combined, may prove more parsimo-
nious, with variation within each Trust class captured
by the continuous latent variable, potentially leading to
fewer Trust classes needed to describe overall Trust-
level variation. Where determination of Trust ranks is
important, the estimation of Trust outcomes is simpler
if the categorical latent variable only is adopted at the
Trust level, avoiding derivation of the normally distribu-
ted effects within each Trust class. Addressing spatial
dependencies amongst the Trusts may nevertheless war-
rant incorporating upper-level effects.
In fixing patient-level latent class composition and
accommodating patient casemix differences, the residual
Trust-class differences in outcome reflect variations in
Trust performance that depend upon Trust characteristics
(differences in the treatments given and healthcare deliv-
ery processes). Model improvement might be feasible with
more patient-level variables, but this would incorporate
incomplete data, which can cause bias. Within a latent
class framework the uncertainty surrounding unrecorded
or unused patient characteristics is modelled explicitly:
‘fuzzy’ matching. Trust-level covariates might explain
some of the Trust-class outcome differences if included.
The optimum number and composition of Trust (and pos-
sibly patient) classes may change with the inclusion/exclu-
sion of different covariates.
The probabilities of Trust class membership in Table 3
were marked, with most Trusts belonging entirely or pre-
dominantly to one Trust class. This is unsurprising, as
there is only a modest difference between the two classes
in median survival, and probabilistic assignment differ-
entiates between the two, providing a class weighted
combined survival rate. It is not feasible, however, for a
Trust to be assigned a class weighted survival rate below
that of the poorer survival class, or above that of the bet-
ter survival class. This is an implicit constraint on the
estimated weighted survival for Trusts allocated entirely
to one of the two classes (e.g. Trust 1). To alleviate this,
more Trust-level classes could be sought, increasing the
number until no Trust had a probabilistic assignment of
exactly one for classes at the extremities of the range of
Trust outcome means. More research is needed, but as
applied here, the estimated ranks are robust.
Although the analyses undertaken were primarily for
illustration of the proposed methodology, the results are
to be taken seriously. Bias may have occurred, however,
due to patients with more than one Trust visit having
been assigned the most recent Trust visited as the
treatment centre. If diagnosis was made at a separate
Trust to that which subsequently provided treatment, it
would be the latter that was important when modelling
healthcare delivery and process variables. In our dataset,
75% of patients visited only one Trust. Nevertheless,
some inaccuracies may remain, which could be
addressed by screening each patient journey to deter-
mine where the majority of interventions take place, or
by using multilevel multiple membership models for
multiple treatment centres. Furthermore, technically, we
have cross-classified data, with patients nested in both
area of residence (which yields the patient SEB) and
diagnostic centre (Trust); the area level is thus crossed
with the Trust level. The number of patients in each
area, however, is small and for simplicity of illustration
we discarded this level in our model. The methodologi-
cal principles of MLLC modelling extend theoretically
to a cross-classified context, but software does not yet
facilitate this.
We have satisfactorily demonstrated the principles of
step (i) outlined previously, but there is more research to
be undertaken to determine the processes for steps
(ii) and (iii), which embark upon modelling patient path-
ways and the evaluation of process differences that vary
across healthcare provider institutions. Distinction could
then be made between the delivery of care (e.g. treat-
ments) and health service process characteristics (e.g.
delays to treatment) that make up the total patient
experience. The proposed methodology paves the way for
a more advanced modelling approach to the analysis of
treatment centre characteristics (in addition to patient
casemix characteristics), where differences in the patient
pathway of care are modelled to evaluate organisational
features in relation to patient outcomes. Such strategies
permit hypothesis generation around which healthcare
delivery and organisational features warrant intervention,
informing prospective cluster-randomised trials targeted
at improving service organisation and delivery. This feeds
into existing approaches for quality improvement
research, consistent with the principles of the MRC fra-
mework for the development and evaluation of complex
interventions [28].
Conclusions
The main advantages of the MLLC approach are that it
provides accurately derived estimates of the outcome dif-
ferences across Trust classes, hence improved ‘casemix
adjustment’ for individual Trusts. Trust level covariates
may be included, capturing additional casemix complex-
ity. Although deliberately simplified, our illustration
demonstrates a principle that could readily extend to a
number of more sophisticated scenarios (e.g. time-to-
event analysis, multiple treatment centres, cross-classified
structures). The MLLC model paves the way to adjust for
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appropriate healthcare), permitting the evaluation of
institutional processes, which should provide a more
robust approach to evaluating institutional performance
than is current practice.
Appendix
The multilevel latent class model used in this study
takes the form:
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where yij is the outcome (death =1 ,alive =0 )f o r
patient i within Trust j; Xij is the vector of patient-
level covariates; t are the Trust classes (1...T); and c are
the patient classes (1...C); p(c|t) is the probability of
being in patient class c conditional on being in Trust
class t, and in this study C is taken as the same for each
Trust. The patient class model, P
(c), expands to:
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where b0
(c) to b5
(c) are the patient-class specific coeffi-
cients for the patient-level covariates.
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